Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q4734170> ?p ?o }
Showing triples 1 to 57 of
57
with 100 triples per page.
- Q4734170 subject Q10090201.
- Q4734170 subject Q7071513.
- Q4734170 subject Q7334131.
- Q4734170 subject Q7335351.
- Q4734170 subject Q8376909.
- Q4734170 subject Q8412954.
- Q4734170 subject Q8533694.
- Q4734170 subject Q8971959.
- Q4734170 abstract "Alogliptin (trade name Nesina in the US and Vipidia in Europe) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, developed by Syrrx, a company which was acquired by Takeda Pharmaceutical Company in 2005. Like other medications for the treatment of Type 2 diabetes, alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.".
- Q4734170 atcPrefix "A10".
- Q4734170 atcSuffix "BH04".
- Q4734170 bioavailability "100.0".
- Q4734170 casNumber "850649-62-6".
- Q4734170 chEBI "72323".
- Q4734170 fdaUniiCode "JHC049LO86".
- Q4734170 iupacName "2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile".
- Q4734170 pubchem "11450633".
- Q4734170 thumbnail Alogliptin.svg?width=300.
- Q4734170 wikiPageExternalLink news_1b8syrrx.html.
- Q4734170 wikiPageWikiLink Q10090201.
- Q4734170 wikiPageWikiLink Q1368197.
- Q4734170 wikiPageWikiLink Q14864419.
- Q4734170 wikiPageWikiLink Q14864427.
- Q4734170 wikiPageWikiLink Q19484.
- Q4734170 wikiPageWikiLink Q202758.
- Q4734170 wikiPageWikiLink Q204711.
- Q4734170 wikiPageWikiLink Q21098968.
- Q4734170 wikiPageWikiLink Q30612.
- Q4734170 wikiPageWikiLink Q417765.
- Q4734170 wikiPageWikiLink Q419770.
- Q4734170 wikiPageWikiLink Q575062.
- Q4734170 wikiPageWikiLink Q6770873.
- Q4734170 wikiPageWikiLink Q7071513.
- Q4734170 wikiPageWikiLink Q7334131.
- Q4734170 wikiPageWikiLink Q7335351.
- Q4734170 wikiPageWikiLink Q8376909.
- Q4734170 wikiPageWikiLink Q8412954.
- Q4734170 wikiPageWikiLink Q8533694.
- Q4734170 wikiPageWikiLink Q8971959.
- Q4734170 wikiPageWikiLink Q899133.
- Q4734170 wikiPageWikiLink Q9368.
- Q4734170 atcPrefix "A10".
- Q4734170 atcSuffix "BH04".
- Q4734170 bioavailability "100.0".
- Q4734170 casNumber "850649".
- Q4734170 chebi "72323".
- Q4734170 iupacName "2".
- Q4734170 pubchem "11450633".
- Q4734170 unii "JHC049LO86".
- Q4734170 type ChemicalSubstance.
- Q4734170 type Drug.
- Q4734170 type ChemicalObject.
- Q4734170 type Thing.
- Q4734170 type Q8386.
- Q4734170 comment "Alogliptin (trade name Nesina in the US and Vipidia in Europe) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, developed by Syrrx, a company which was acquired by Takeda Pharmaceutical Company in 2005. Like other medications for the treatment of Type 2 diabetes, alogliptin does not decrease the risk of heart attack and stroke.".
- Q4734170 label "Alogliptin".
- Q4734170 depiction Alogliptin.svg.